Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRME
#2354
Prime Medicine, Inc. Common Stock
4.6
2
+7.94%
Sector:
Base:
Profit Currency:
Daily Range
Year Range
Daily Change
+7.94%
Monthly Change
+6.21%
6 month change
+35.48%
Year Change
+87.04%
Previous Close
4.2
8
Open
4.6
2
Bid
Ask
Low
4.6
2
High
4.6
2
Volume
111
Markets
US Stock Market
Healthcare
PRME
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
2022
2023
2024
TTM
Key stats
Total common shares outstanding
97.25 M
119.94 M
131.16 M
—
Valuation ratios
Enterprise value
1.52 B
1.01 B
200.51 M
1.58 B
Price to earnings ratio
-4.19
-4.02
-1.77
-8.44
Price to sales ratio
—
4 743.4
116.1
359.19
Price to cash flow ratio
-4.51
-4.82
-2.82
-15.09
Price to book ratio
1.88
5.99
2.26
4.68
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
0.34
1.02
0.66
0.62
Return on equity %
0.39
1.49
1.28
1.94
Return on invested capital %
623.13
1 100.7
952.9
—
Gross margin %
—
100
100
400
Operating margin %
—
121.9 K
6 787.36
14.82 K
EBITDA margin %
—
—
—
—
Net margin %
—
117.94 K
6 566.61
14.35 K
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
11.1
2.53
5.58
20.52
Inventory turnover
—
—
—
—
Asset turnover
0
0
0.01
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
3.89
1.82
1.04
0.78
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
8.67
1.34
1.61
4.82
Net current asset value per share
8.75
1.57
1.79
5.42
Tangible book value per share
9.33
1.46
1.29
3.59
Working capital per share
7.96
0.95
1.47
4.35
Book value per share
9.33
1.46
1.29
3.59
News
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Prime Drink Group completes first closing of private placement
Prime: Maintaining "Buy" On Solidified Catalysts For Wilson's Disease And Beyond
Prime Drink Group announces private placement to raise up to $5 million
Goldman Sachs reiterates Early-Stage Biotech rating on Prime Medicine stock
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine appoints Matthew Hawryluk as chief business officer
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
Prime Medicine Momentum Amid Pipeline Progress: Why I Choose To 'Hold' For Now (PRME)
Cathie Wood’s ARK ETF adjusts stock positions, buys PRME and TWST
Prime Drink Group shifts from rights offering to private placement
Google, Apple Lead Mega-Cap Movers on a Volatile Wednesday